Cargando…

EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib

BACKGROUND: Gastrointestinal stromal tumors (GISTs) are rare, but represent the most common mesenchymal neoplasms of the gastrointestinal tract. EPIdemiology GIST, is an observational multicenter longitudinal follow-up cohort study reporting the prescribing patterns of imatinib in patients with GIST...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouché, Olivier, Cesne, Axel Le, Rios, Maria, Chaigneau, Loic, Italiano, Antoine, Duffaud, Florence, Lecomte, Thierry, Arsène, Dominique, Manfredi, Sylvain, Aparicio, Thomas, Remy, Stéphane, Isambert, Nicolas, Collard, Olivier, Priou, Frank, Bertucci, François, Sambuc, Roland, Bisot-Locard, Ségolene, Bourges, Olivier, Chabaud, Sylvie, Blay, Jean-Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143255/ https://www.ncbi.nlm.nih.gov/pubmed/30226855 http://dx.doi.org/10.1371/journal.pone.0204117

Ejemplares similares

Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program
por: Blay, Jean-Yves, et al.
Publicado: (2013)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
por: Adenis, A., et al.
Publicado: (2014)

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017)

Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group
por: Huynh, Thanh-Khoa, et al.
Publicado: (2014)

Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study
por: Smith, Denis, et al.
Publicado: (2022)

The off-label use of targeted therapies in sarcomas: the OUTC’S program
por: Eberst, Lauriane, et al.
Publicado: (2014)

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)(†)
por: Bompas, E., et al.
Publicado: (2015)

Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
por: Duffaud, Florence, et al.
Publicado: (2012)

Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years
por: Basse, Clémence, et al.
Publicado: (2019)

Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study
por: Le Cesne, A., et al.
Publicado: (2023)

Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib
por: Moryoussef, Frédérick, et al.
Publicado: (2015)

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
por: Blesius, Aurore, et al.
Publicado: (2011)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022)

Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study
por: Bompas, Emmanuelle, et al.
Publicado: (2018)

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)
por: Patrikidou, Anna, et al.
Publicado: (2020)

PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target
por: Bertucci, François, et al.
Publicado: (2019)

Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment
por: Boilève, Alice, et al.
Publicado: (2020)

Recent advances in managing gastrointestinal stromal tumor
por: Duffaud, Florence, et al.
Publicado: (2017)

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
por: Boudin, Laurys, et al.
Publicado: (2022)

Targeting the VEGF Pathway in Osteosarcoma
por: Assi, Tarek, et al.
Publicado: (2021)

Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
por: Lebellec, Loïc, et al.
Publicado: (2018)

A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome
por: Rochefort, Pauline, et al.
Publicado: (2017)

Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study
por: Gelderblom, Hans, et al.
Publicado: (2020)

Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal
por: Duffaud, F, et al.
Publicado: (2010)

REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis
por: Berry, Vincent, et al.
Publicado: (2017)

A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery
por: Pautier, P., et al.
Publicado: (2021)

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma
por: Maillard, Maud, et al.
Publicado: (2020)

COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)
por: Di Fiore, Frederic, et al.
Publicado: (2020)

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013)

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2022)

Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study
por: Zaanan, Aziz, et al.
Publicado: (2023)

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate
por: Pautier, Patricia, et al.
Publicado: (2013)

Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)
por: Moreau-Bachelard, C., et al.
Publicado: (2022)

Clinical, Pathological, and Molecular Characteristics in Colorectal Cancer
por: Dedieu, Stéphane, et al.
Publicado: (2022)

Determinants of the access to remote specialised services provided by national sarcoma reference centres
por: Fayet, Yohan, et al.
Publicado: (2021)

Management of imatinib-associated skin rash in a patient with metastatic gastrointestinal stromal tumor: a case report
por: Blay, Jean-Yves
Publicado: (2012)

Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib
por: Stacchiotti, Silvia, et al.
Publicado: (2013)

No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks’ Outcome?
por: Fayet, Yohan, et al.
Publicado: (2022)

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
por: Cassier, P A, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_b7q3jk79u03ac3b3eplvc9jep7